Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 4

From BugSigDB


Reviewed Marked as Reviewed by Folakunmi on 2024-2-4

Curated date: 2021/01/10

Curator: WikiWorks

Revision editor(s): Claregrieve1, WikiWorks, Folakunmi

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Lung Pulmo,Lung,lung
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Lung cancer alveolar cell carcinoma,cancer of lung,lung cancer,lung cancer, protection against,lung neoplasm,malignant lung neoplasm,malignant lung tumor,malignant neoplasm of lung,malignant neoplasm of the lung,malignant tumor of lung,malignant tumor of the lung,Nonsmall cell lung cancer,Lung cancer
Group 0 name Corresponds to the control (unexposed) group for case-control studies
control group with no antibiotics
Group 1 name Corresponds to the case (exposed) group for case-control studies
cancerous site with no antibiotics
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
patients who have diagnosis of lung cancer established by histological confirmation
Group 0 sample size Number of subjects in the control (unexposed) group
8
Group 1 sample size Number of subjects in the case (exposed) group
13
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
3 months

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
LEfSe
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
3.5

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
decreased
Simpson Estimator of species richness and species evenness: more weight on species evenness
increased

Signature 1

Reviewed Marked as Reviewed by Folakunmi on 2024-2-2

Curated date: 2021/01/10

Curator: Fatima Zohra

Revision editor(s): Claregrieve1, WikiWorks

Source: Supplemental Figure S1

Description: Significant bacterial difference between To (samples from cancerous site who received no antibiotics prior to 3 months) and No (normal samples who received no antibiotics)

Abundance in Group 1: increased abundance in cancerous site with no antibiotics

NCBI Quality ControlLinks
Capnocytophaga

Revision editor(s): Claregrieve1, WikiWorks

Signature 2

Reviewed Marked as Reviewed by Folakunmi on 2024-2-2

Curated date: 2021/01/10

Curator: Fatima Zohra

Revision editor(s): Claregrieve1, WikiWorks

Source: Supplemental Figure S1

Description: Significant bacterial difference between To (samples from cancerous site who received no antibiotics prior to 3 months) and No (normal samples who received no antibiotics)

Abundance in Group 1: decreased abundance in cancerous site with no antibiotics

NCBI Quality ControlLinks
Comamonadaceae
Deltaproteobacteria
Moraxellaceae
Myxococcales
Paracoccus
Paracoccaceae
Rhodobacterales
Staphylococcaceae
Staphylococcus
Pseudomonadales
Burkholderiales
Alphaproteobacteria
Chitinophagaceae
Clostridia
Clostridiales bacterium
Bacteroidota
Hydrotalea

Revision editor(s): Claregrieve1, WikiWorks